News

Filter

Current filters:

NicOxFinancial

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

30-10-2014

French pharma company NicOx has achieved sales of 4 million euros ($5 million) in the third quarter of…

FinancialFranceNicOxOphthalmicsPharmaceutical

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

25-09-2014

Canada’s Valeant Pharmaceuticals International and France’s NicOx have reported positive top-line…

Bausch & LombCanadaFinancialFranceNicOxOphthalmicsPharmaceuticalResearchValeant Pharmaceuticals InternationalVesneo

NicOx highlights progress in bid to focus on ophthalmology

07-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) says it has made significant progress in 2013…

BiotechnologyFinancialFranceNicOxOphthalmics

NicOx earns $10M milestone under Bausch & Lomb accord

13-03-2012

French biotechnology firm NicOx (Euronext Paris: COX) will receive a $10 million milestone from US partner…

Bausch & LombBiotechnologyFinancialNicOxOphthalmicsPharmaceuticalResearch

NicOx says it is “well funded” and has robust pipeline, despite recent disappointment with naproxcinod

20-05-2010

French biotechnology firm NicOx remains confident about its future, despite the recent negative opinion…

BiotechnologyFinancialLicensingnaproxcinodNicOxPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top